Could a simple blood test predict esophageal cancer?

NCT ID NCT00260585

Recruiting now Knowledge-focused Sponsor: University of Pittsburgh Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting medical history, blood, and tissue samples from 7,000 people with esophageal disorders like GERD or Barrett's esophagus. Researchers hope to find genetic or protein markers that signal a higher risk of developing esophageal cancer. The goal is to enable earlier detection and improve survival chances.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help identify people at high risk for esophageal cancer earlier, potentially leading to better survival through early detection.
What could go wrong: This is an observational registry, not a treatment trial. It may not directly lead to new tests or prevention strategies, and results could take many years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARRETT'S METAPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

achalasia Barrett esophagus Esophageal Achalasia esophageal cancer esophageal disorder Esophageal Neoplasms gastroesophageal junction adenocarcinoma gastroesophageal reflux disease hiatus hernia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL ACHALASIA ESOPHAGEAL CANCER ESOPHAGEAL DISEASES GASTROESOPHAGEAL REFLUX DISEASE (GERD) HIATAL HERNIA

Contacts and locations

Locations

Department of Cardiothoracic Surgery
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.